At a glance
ClinicalIndex Comparison RecordN/ACompleted· 31 enrolled
Drug / intervention
epoetin alfabiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Institution, Open-Label, Nonrandomized Pilot Study of High Dose Epoetin Alfa Administered Once a Week in Patients With Multiple Myeloma: Its Effects on Hemoglobin, Blood Transfusion Requirements and Quality of Life
In Brief
A clinical study evaluating epoetin alfa for Anemia and 2 related conditions. Completed, enrolled 31 participants across 1 site.
Detailed Summary
RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia in patients with multiple myeloma. PURPOSE: This clinical trial is studying how well epoetin alfa works in treating anemia in patients undergoing chemotherapy for multiple myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, Multiple Myeloma, Plasma Cell Neoplasm
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2003
First PostedNov 2006
Primary CompletionJan 2009
Study CompletionAug 2013
TodayJul 2026
First PostedNov 17, 2006
Enrollment StartSep 1, 2003
Primary CompletionJan 1, 2009
Study CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 19.6 years ago
Interventions
epoetin alfabiological
Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.